Press Release on Q4FY26 Audited Financial Results
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 17.4 pts more than Nifty Smallcap 250 and 16.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Gland Pharma reported record revenues and profitability for Q4FY26 with consolidated revenue of ₹17,428 million, up 22% YoY. Full year FY26 revenue stood at ₹64,307 million, growing 14.5%. The company saw exceptional PAT growth with Q4 adj. PAT at ₹3,667 million (up 97% YoY) and FY26 adj. PAT at ₹10,455 million (up 50% YoY). EBITDA margin expanded significantly with Q4 adj. EBITDA margin at 30% (vs 24% in Q4FY25) and FY26 at 26% (vs 23% in FY25). CDMO business contributed 46% of revenues and grew 36% YoY in Q4FY26. The company launched 31 products in the US during FY26 and filed 24 ANDAs with 28 approvals. The Board recommended a final dividend of ₹20 per share. USA remains the largest market contributing ₹9,807 million in Q4.
Strong quarter with double-digit revenue growth and near-doubling of PAT demonstrates operational leverage and successful CDMO ramp-up. Margin expansion signals improving profitability and should be positive for the stock.